Ogivri (Trastuzumab-Dkst) Patent Expiration, LOE Window & CMS Spending

Ogivri (Trastuzumab-Dkst) by Viatris: Biologic BLA (Purple Book Regime), 0 AB generics, $20.4M 2024 CMS Part D & Medicaid spend, and $2,625 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorViatris
FDA Application & PathwayB761074 (BLA)
Exclusivity / Cliff HorizonBiologic BLA (Purple Book Regime)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$20.4M
2024 Medicare Part D Spend$1.0M
2024 Medicaid Spend$19.4M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($2,625 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Viatris across sibling Meru public-data platforms.